Table 8.
Clinical trials of bispecific T-cell-engaging constructs in lymphoma.
| Trial ID (Name) | Authors | Year | Intervention(s) | Target(s) | Format | Phase | Disease(s) | N | CR | OR | PFS |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00274742 | Goebeler et al. | 2016 | Blinatumomab | CD3 × CD19 | BiTE | I | FL MCL DLBCL |
15 7 11 |
40% 43% 36% |
80% 71% 55% |
N.A. |
| NCT01741792 | Viardot et al. | 2016 | Blinatumomab | CD3 × CD19 | BiTE | II | DLBCL | 21 | 19% | 43% | median 3.7 months |
| NCT02910063 | Coyle et al. | 2020 | Blinatumomab | CD3 × CD19 | BiTE | II | B-NHL | 41 | 22% | 37% | median 8.4 months a |
| NCT02568553 | Poh et al. | 2019 | Blinatumomab + Lenalidomide | CD3 × CD19 | BiTE | I | B-NHL | 18 | 50% | 83% | median 8.3 months |
| NCT03023878 | Katz et al. | 2019 | Blinatumomab after R-chemotherapy | CD3 × CD19 | BiTE | II | DLBCL | 28 | N.A. | 89% | N.A. |
|
NCT03931642 (BLINART) |
Guieze et al. | 2020 | Blinatumomab after R-CHOP | CD3 × CD19 | BiTE | II | CLL with RT | 5 | 40% | 60% | N.A. |
|
NCT03075696 (NP30179) |
Morschhauser et al. | 2019 | Glofitamab and Obinutuzumab | CD3 × CD20 | BsAb | I/Ib | B-NHL (all patients) B-NHL (highest dose) |
21 10 |
43% 80% |
48% 90% |
N.A. |
|
NCT03075696 (NP30179) |
Hutchings et al. | 2020 | Glofitamab and Obinutuzumab | CD3 × CD20 | BsAb | I/Ib | aggressive B-NHL indolent B-NHL |
24 8 |
29% 75% |
50% 100% |
N.A. |
| NCT02290951 | Bannerji et al. | 2018 | Odronextamab (REGN1979) | CD3 × CD20 | BsAb | I | DLBCL FL MCL |
15 7 2 |
0% 71% 0% |
40% 100% 100% |
N.A. |
| NCT02290951 | Bannerji et al. | 2020 | Odronextamab (REGN1979) | CD3 × CD20 | BsAb | I | FL (≥5 mg) FL (≥80 mg) DLBCL (no prior CAR, ≥5 mg) DLBCL (no prior CAR, ≥80 mg) DLBCL (relapse after CAR, ≥5 mg) DLBCL (relapse after CAR, ≥80 mg) |
28 16 30 10 23 21 |
75% 69% 30% 60% 22% 24% |
93% 94% 47% 60% 30% 33% |
median 12.8 months median 12.8 months median 5.1 months median 11.1 months median 2.5 months median 2.5 months |
| NCT03625037 | Hutchings et al. | 2020 | Epcoritamab (GEN3013, SQ) | CD3 × CD20 | BsAb | I/II | DLBCL FL |
18 8 |
33% 25% |
67% 100% |
N.A. |
|
NCT02500407 (GO29781) |
Schuster et al. | 2019 | Mosunetuzumab (RG7828) | CD3 × CD20 | BsAb | I/Ib | aggressive B-NHL indolent B-NHL |
119 64 |
19% 42% |
35% 64% |
N.A. |
|
NCT02500407 (GO29781) |
Assouline et al. | 2020 | Mosunetuzumab (RG7828) | CD3 × CD20 | BsAb | I/Ib | FL | 62 | 50% | 68% | median 11.8 months |
|
NCT02500407 (GO29781) |
Matasar et al. | 2020 | Mosunetuzumab (RG7828, SQ) | CD3 × CD20 | BsAb | I/Ib | aggressive B-NHL indolent B-NHL |
15 7 |
20% 29% |
60% 86% |
N.A. |
|
NCT03677154 (GO40554) |
Olszewski et al. | 2020 | Mosunetuzumab (RG7828) | CD3 × CD20 | BsAb | I/II | untreated DLBCL | 19 | 42% | 58% | N.A. |
|
NCT03677141 (GO40515) |
Phillips et al. | 2020 | Mosunetuzumab (RG7828) + CHOP | CD3 × CD20 | BsAb | I/II | B-NHL untreated DLBCL |
7 36 |
71% 85% |
86% 96% |
N.A. |
All disease groups are relapsed/refractory unless otherwise specified. a For patients who achieved CR. Abbreviations: N, number of patients; CR, complete response, OR, overall response; PFS, progression free survival; N.A., not assessed.